Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link.
Erectile dysfunction (ED) and benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) share many epidemiologic and clinical similarities. First-line therapy for both conditions include oral medications (alpha blockers, phosphodiesterase inhibitors). The impetus to develop and use questionnaires to characterize these two conditions is based on the trend away from invasive diagnostic testing to the use of patient-reported outcomes or validated self-administered questionnaires. The International Prostate Symptom Score, the International Index of Erectile Function, the Male Sexual Health Questionnaire (MSHQ) and the MSHQ short form are similar patient-reported assessment questionnaires used for research or clinical evaluation of BPH/LUTS, ED and ejaculatory dysfunction. These patient-based self-administered questionnaires are likely to assume an ever increasing important role in the future, as oral BPH therapies are considered for the treatment of ED and oral ED therapies are considered for the treatment of BPH/LUTS.
Rosen
R C
RC
New England Research Institutes, Watertown, MA 02472, USA. rrosen@neriscience.com
Seftel
A D
AD
D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology / Q000503:physiopathology*; D011795:Surveys and Questionnaires; D014570:Urologic Diseases / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology / Q000503:physiopathology*
D010726:Phosphodiesterase Inhibitors